KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Deferred Revenue (2019 - 2025)

Esperion Therapeutics' Current Deferred Revenue history spans 7 years, with the latest figure at $34.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 304.75% year-over-year to $34.5 million; the TTM value through Dec 2025 reached $34.5 million, up 304.75%, while the annual FY2025 figure was $34.5 million, 304.75% up from the prior year.
  • Current Deferred Revenue reached $34.5 million in Q4 2025 per ESPR's latest filing, up from $30.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $34.5 million in Q4 2025 to a low of $2.5 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $13.5 million, with a median of $10.3 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: soared 624.32% in 2023, then tumbled 84.52% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $5.7 million in 2021, then tumbled by 38.29% to $3.5 million in 2022, then skyrocketed by 624.32% to $25.4 million in 2023, then crashed by 66.47% to $8.5 million in 2024, then skyrocketed by 304.75% to $34.5 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Current Deferred Revenue are $34.5 million (Q4 2025), $30.7 million (Q3 2025), and $22.3 million (Q2 2025).